Treatment of intracranial aneurysms using the new Surpass Evolve flow diverter: Safety outcomes and six-month imaging follow-up - 10/02/22
, Kemal Alpay c, Matias Sinisalo a, Jussi Numminen dBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
| páginas | 7 |
| Iconografías | 3 |
| Vídeos | 0 |
| Otros | 0 |
Graphical abstract |
Highlights |
• | This study reports the results with the longest radiographic follow-up of the new Surpass Evolve flow diverter. |
• | Our results demonstrate encouraging technical success and good radiological outcomes. |
• | Favorable aneurysm occlusion (O’Kelly Marotta grading scale C-D) at six month follow-up was achieved in 21/27 (78%) aneurysms. |
Abstract |
Background and purpose |
Several studies have reported good long-term results in the occlusion of intracranial aneurysms with flow diverter treatment. The aim of this study was to report the safety and six-month follow-up outcomes using the new Surpass Evolve flow diverter in the treatment of intracranial aneurysms.
Materials and methods |
Consecutive patients with intracranial aneurysm treated with Surpass Evolve flow diverter in two high-volume neurovascular centers between May 2019 and January 2020 were retrospectively reviewed. Procedure-related complications, aneurysm occlusion (O’Kelly-Marotta grading scale), and clinical outcomes were assessed.
Results |
Twenty-nine patients with 30 aneurysms were included in the study. Favorable aneurysm occlusion (O’Kelly Marotta grading scale C-D) at six-month follow-up was achieved in 21/27 (78%) aneurysms. No clinical procedure related thromboembolic complications were encountered. Twenty-three out of 24 patients with unruptured aneurysms treated with Surpass Evolve remained clinically intact at clinical follow-up. There was one fatal hemorrhagic procedure-related complication (3%). In five patients with ruptured aneurysms, no early or late rebleeds occurred from the aneurysms.
Conclusions |
Surpass Evolve FD worked technically well with no intraprocedural thromboembolic complications and occlusion rates comparable to other FDs.
El texto completo de este artículo está disponible en PDF.Keywords : Aneurysm, Intracranial, Endovascular, Flow diverter, Surpass Evolve
Abbreviations : ACT, FD, mRS, OKM
Esquema
Vol 49 - N° 1
P. 80-86 - janvier 2022 Regresar al número
Artículo precedente
- Diagnostic efficacy and safety of gadoteridol compared to gadobutrol and gadoteric acid in a large sample of CNS MRI studies at 1.5 T
- Anna del Poggio, Giulia Anello, Sonia Francesca Calloni, Paolo Vezzulli, Clodoaldo Pereira, Antonella Iadanza, Andrea Falini, Nicoletta Anzalone
- Factors related to microcatheter passage through the trans-cell approach using a low-profile visualized intraluminal support device: an in-vitro study
- Hiroyuki Ikeda, Masanori Kinosada, Yoshitaka Kurosaki, Akira Handa, Masaki Chin, Sen Yamagata
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?